The outcome? Reduced hunger, effortless smaller portion sizes, and a metabolism optimized to burn calories faster
The combination allows researchers to investigate dual-pathway mechanisms for cellular repair, monitor regenerative processes, and evaluate recovery outcomes
McCoy The cohort included 351,913 adults aged 21 years and older with type 2 diabetes and moderate risk for CVD who filled an initial prescription for a GLP-1 drug , SGLT2 inhibitor, DPP-IV inhibitor or sulfonylurea from 2014 to 2021 (mean age, 65.3 years
Saman Rahmanian congratulations Oral GLP-1 therapy that demonstrates efficacy comparable to injectable versions is rare in obesity care-this marks a shift from biologic-dominant treatment to pill-based options, lowering treatment burden for patients
doi: 10.1016/j.bbadis.2009.09.007 60
( Epub 20201007 )